Lepodisiran

From the Economist newsletter:

Cardiologists reported that an experimental drug, lepodisiran, manufactured by Eli Lilly, an American pharmaceutical company, could lower by 94% the blood’s level of a genetically inherited particle that greatly increases the risk of heart attacks and strokes. The promising midstage trial results will now be tested in large clinical trials. An estimated 1.4bn people worldwide have elevated levels of the particle, Lp(a).